MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s40261-025-01515-x

Медицинская библиотека · Clinical drug investigation · 2026

Safety and Pharmacokinetics of Repeat Dosing of Long-Acting SARS-CoV-2 Antibodies Tixagevimab/Cilgavimab (AZD7442): Results from the PROVENT Sub-study.

Ustianowski Andrew, Levin Myron J, De Wit Stephane, Launay Odile, Veekmans Bernard, Rampling Tommy, Sullivan James G, Vishnepolsky Mark, Wijewardane Priyantha, Fawadleh Yousef, Zhang Huixia, Li Meng, Wickramarachchi Dilki, Sharbaugh Audrey, Beavon Rohini, Thissen Jesse, Hirao Lauren, Dzutseva Vitalina, Seegobin Seth, Streicher Katie, Kiazand Alexandre, Esser Mark T, Chang Lee-Jah, Perez John L, Cohen Taylor S

Клиническое исследование III фазыСтатьяМногоцентровое исследованиеРандомизированное исследованиеПеревод пока не подготовлен

Аннотация

BACKGROUND AND

OBJECTIVES

The PROVENT study demonstrated the efficacy and safety of a single 300-mg dose of AZD7442 (tixagevimab/cilgavimab) for pre-exposure prophylaxis of COVID-19 in at-risk individuals. Here we report an analysis of repeat dosing of intramuscular AZD7442 300 and 600 mg from the PROVENT sub-study.

METHODS

The sub-study enrolled eligible participants from the parent study, creating four sub-study groups. Group 1 received AZD7442 300 mg in PROVENT followed by one 300-mg dose in the sub-study (10-14 months apart). Group 2 received placebo in PROVENT followed by two AZD7442 300-mg doses 6 months apart in the sub-study. Group 3a received AZD7442 300 mg in PROVENT followed by one 300-mg dose and two 600-mg doses 6 months apart in the sub-study. Group 3b received placebo in PROVENT followed by one 300-mg dose and two 600-mg doses 6 months apart in the sub-study. The primary endpoint was safety. Secondary endpoints included pharmacokinetics and anti-drug antibody (ADA) responses.

RESULTS

Adverse events (AEs) and serious AEs (SAEs) were reported in 75.7-81.5% and 13.2-16.8% of participants, respectively. AZD7442-related AEs, SAEs, and AEs of special interest occurred in 1.4-5.3%, 0-0.2%, and 0-5.3% of participants, respectively, and 3.9-6.7% experienced ≥ 1 cardiac and/or thromboembolic SAE. AZD7442 serum concentrations were dose-dependent with minimal accumulation following redosing, and 4.1-10.7% had treatment-emergent ADAs to AZD7442.

CONCLUSIONS

AZD7442 safety, pharmacokinetic, and ADA response profiles were similar regardless of repeat dosing schedule, and consistent with single-dose study data. These results may support future use of long-acting antibodies.

GOV REGISTRATION: NCT04625725.

Для цитирования: Ustianowski Andrew, Levin Myron J, De Wit Stephane, Launay Odile, Veekmans Bernard, Rampling Tommy, Sullivan James G, Vishnepolsky Mark, Wijewardane Priyantha, Fawadleh Yousef, Zhang Huixia, Li Meng, Wickramarachchi Dilki, Sharbaugh Audrey, Beavon Rohini, Thissen Jesse, Hirao Lauren, Dzutseva Vitalina, Seegobin Seth, Streicher Katie, Kiazand Alexandre, Esser Mark T, Chang Lee-Jah, Perez John L, Cohen Taylor S. Safety and Pharmacokinetics of Repeat Dosing of Long-Acting SARS-CoV-2 Antibodies Tixagevimab/Cilgavimab (AZD7442): Results from the PROVENT Sub-study.. Clinical drug investigation. 2026. DOI: 10.1007/s40261-025-01515-x.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.